# Rarecells

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rarecells

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.rarecells.com
- Total disclosed funding: $8M
- Latest round: Series A (Jul 22, 2021)
- Investors on record: 2

## About

Rarecells is a biotechnology company focused on advancing liquid biopsy technology for early cancer detection, utilizing innovative methods to analyze blood samples and identify circulating tumor cells.Rarecells, founded in 2010 in Paris, France, specializes in liquid biopsy solutions aimed at cancer diagnostics. The company has not undergone notable pivots or changes in its business strategy since its inception. It has successfully raised capital through two funding deals, with the most recent deal occurring on December 9, 2021, where it secured USD 13.00 mn in Series A funding. The CEO of Rarecells is Thierry Baglan.Rarecells specializes in innovative liquid biopsy technology, primarily through its flagship product, the ISET® technology, which enables the early detection of cancer by analyzing blood samples. This non-invasive method captures early signals of cancer by identifying circulating tumor cells (CTCs) in bodily fluids, providing a significant advantage over traditional tissue biopsies. The ISET® technology has been developed over more than a decade and is CE-IVD certified, making it suitable for clinical applications across various cancer types. Rarecells collaborates with diagnostic and pharmaceutical companies to enhance the accessibility of their tests, primarily targeting markets in the United States and Europe. Their core client base consists of healthcare institutions, research centers, and hospitals that prioritize early cancer detection as a means to improve patient outcomes.Rarecells generates revenue through partnerships and collaborations with diagnostic and pharmaceutical companies that utilize its ISET® technology in their cancer detection and treatment protocols. The transaction structure is primarily B2B, where healthcare organizations purchase services based on their specific needs for cancer diagnostics. Pricing plans for the ISET® technology are structured around the volume of tests ordered and the scope of service agreements established with partner organizations. This model allows Rarecells to scale its offerings according to demand, ensuring that healthcare providers have access to cutting-edge cancer detection tools. Revenue is derived from the successful integration of its technology into clinical practices, thereby facilitating routine cancer screenings and contributing to overall improved healthcare delivery.In December 2021, Rarecells raised USD 13.00 mn in Series A funding, which will be utilized to initiate laboratory and clinical operations in the United States, focusing specifically on early detection tests for Prostate Cancer and Acute Myeloid Leukemia. The company aims to expand its market presence by introducing its innovative diagnostic tests to healthcare providers across North America, with plans to commence these operations in the near future.

## Funding rounds

- Series A, Jul 22, 2021, $8M — Globivest, Yaday

## Investors

- Globivest (https://capitalatlas.ai/funds/globivest) — Series A
- Yaday (https://capitalatlas.ai/funds/yaday) — Series A